This study investigates advanced pancreatic cancer with normal CA19-9 levels.
The study evaluates the effectiveness of combining mFOLFIRINOX with radiotherapy in patients who have this specific cancer profile.
- Who can participate: Adults aged 18 to 80 with advanced pancreatic adenocarcinoma and normal CA19-9 levels can participate. Participants must not have received prior anti-tumor therapy and should meet specific health criteria.
- Study details: Participants will receive mFOLFIRINOX plus radiotherapy. A placebo is not used in this study.